Adrenomedullin (ADM) inhibits endothelial insulin signaling, contributing to obesity-associated insulin resistance, according ...

Researchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.

Adrenomedullin disrupts insulin signaling in blood vessels, leading to systemic insulin resistance in obesity-associated type 2 diabetes.

Olive oil bioactives, including MUFAs, polyphenols, and triterpenoids, modulate gene expression linked to insulin sensitivity ...

If insulin can’t get out of blood vessels, it can’t act in its target tissues. “Endothelial cells are full of insulin ...

Announcing a new article publication for BIO Integration journal.   Diabetes, a common metabolic condition, poses a substantial health burden worldwide. To revolutionize diabetes management, enhance ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...